PK-enhanced PI-Kinase (PI4K; PI5K) Inhibitors of RNA Viruses

$1,341,829U19FY2018AINIH

Stanford University, Stanford CA

Investigators

Linked publications, trials & patents

Paper 38294906 Paper 37581931 Paper 37390827 Paper 37259914 Paper 37180102 Paper 36653124 Paper 36543117 Paper 35982307 Paper 35759523 Paper 35346346 Paper 35189047 Paper 35087093 Paper 35058616 Paper 34551964 Paper 34551963 Paper 34529084 Paper 34193258 Paper 34155143 Paper 34054824 Paper 34017121 Paper 34002093 Paper 33952674 Paper 33871421 Paper 33691026 Paper 33298607 Paper 33173007 Paper 33137362 Paper 32997652 Paper 32576678 Paper 32226009 Paper 32132525 Paper 32064341 Paper 31971918 Paper 31969487 Paper 31945771 Paper 31915244 Paper 31722210 Paper 31562126 Paper 31527793 Paper 31420268 Paper 31384002 Paper 31350390 Paper 31013272 Paper 30935881 Paper 30814731 Paper 30770827 Paper 30768832 Paper 30759391 Paper 30699342 Paper 30646264 Paper 30626964 Paper 30555904 Paper 30413720 Paper 30228122 Paper 30149262 Paper 30135583 Paper 30107138 Paper 30078634 Paper 30043139 Paper 29960011 Paper 29898768 Paper 29888341 Paper 29883610 Paper 29753658 Paper 29706550 Paper 29649437 Paper 29629118 Paper 29618496 Paper 29589830 Paper 29537985 Paper 29535204 Paper 29358745 Paper 29343568 Paper 29337789 Paper 29298032 Paper 29275860 Paper 29241533 Paper 29148875 Paper 29104927 Paper 28942130 Paper 28809547 Paper 28746868 Paper 28692267 Paper 28679762 Paper 28672171 Paper 28662753 Paper 28570275 Paper 28458037 Paper 28420884 Paper 28419265 Paper 28377596 Paper 28331092 Paper 28329704 Paper 28324666 Paper 28306259 Paper 28291107 Paper 28240606 Patent 9926309 Patent 9364484 Patent 9309236

Abstract

Our goal is to develop broad spectrum, small molecule antivirals with high barriers to resistance against multiple Priority Pathogens. We discovered a novel specific phosphoinositide (PI)-4,5-bisphosphate (PI(4,5)P2, or

View original record on NIH RePORTER →